OpenAI și Anthropic deschid un nou front de business. Giganții AI intră masiv în Biotehnologie • Newsweek România

OpenAI and Anthropic are expanding their competition into biotechnology, focusing on advanced algorithms for drug discovery and genetic research. This strategic shift aims to reduce the time needed to identify candidate molecules for treating rare diseases and cancers. Both companies are forming partnerships with major pharmaceutical firms to access vast clinical databases. OpenAI has acquired Orchestra Bio, while Anthropic has taken over Coefficient Bio, indicating a race in biotech. However, experts warn of security risks and ethical dilemmas associated with AI's dual-use potential in creating both beneficial and harmful biological compounds.